Annexon Says "ANX005 75 mg/kg outperformed placebo on multiple endpoints, however, it was not statistically significant on the primary endpoint of GBS-DS at week 8"
Portfolio Pulse from Benzinga Newsdesk
Annexon announced that its drug ANX005 at 75 mg/kg outperformed placebo on multiple endpoints in a clinical trial, but did not achieve statistical significance on the primary endpoint of GBS-DS at week 8.
June 04, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Annexon's drug ANX005 showed better performance than placebo on several endpoints in a clinical trial, but failed to achieve statistical significance on the primary endpoint of GBS-DS at week 8.
The failure to achieve statistical significance on the primary endpoint is likely to be viewed negatively by investors, despite the drug's better performance on multiple other endpoints. This could lead to a short-term decline in Annexon's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100